Acquisitions (Tables)

12 Months Ended

Dec. 31, 2022

2021 Acquisitions

Acquisitions

Schedule of Components and Fair Value Allocation of the Consideration Transferred in Connection with Acquisitions

	SCI Instruments			Molecubes NV
Segment	BSI Nano			BSI BioSpin
Consideration Transferred:
Cash paid	$	28.0		$	21.1
Fair value of contingent consideration		1.0			0.4
Working capital adjustment		(0.6	)		—
Total consideration transferred	$	28.4		$	21.5
Allocation of Consideration Transferred:
Cash	$	—		$	1.1
Accounts receivable		—			1.2
Inventories		1.0			1.5
Other current assets		—			0.3
Property, plant and equipment		—			0.1
Intangible assets:
Technology		7.1			3.4
Customer relationships		6.4			2.4
Trade name		0.4			0.5
Backlog		1.2			0.1
Goodwill		12.6			14.1
Deferred taxes		—			(1.6	)
Liabilities assumed		(0.3	)		(1.6	)
Total consideration allocated	$	28.4		$	21.5

Schedule of Consideration Transferred and the Respective Reporting Segment for Each Acquisition

In addition to the SCI and Molecubes acquisitions, in 2021 the Company completed various other acquisitions accounted for under the acquisition method that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for these acquisitions (in millions):

Name of Acquisition	Date Acquired	Segment	Total Consideration		Cash Consideration
Creative Instruments	July 1, 2021	BSI CALID	$	1.0	$	1.0
SVXR, Inc	September 9, 2021	BSI Nano		13.4		11.9
			$	14.4	$	12.9

In addition to the acquisitions noted above, in 2021 the Company completed minority strategic investments that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions):

Name	Acquisition / Investment	Financial Statement Classification	Date Acquired	Segment	Total Consideration		Cash Consideration
Glycopath Inc.	Investment	Other long-term assets	February 18, 2021	BSI CALID	$	2.0	$	2.0
IonPath Inc.	Investment	Other long-term assets	March 18, 2021	BSI CALID		2.0		2.0
Olaris, Inc.	Investment	Other long-term assets	September 23, 2021	BSI BioSpin		0.5		0.5
					$	4.5	$	4.5

2022 Acquisitions

Acquisitions

Schedule of Components and Fair Value Allocation of the Consideration Transferred in Connection with Acquisitions

The following table reflects the consideration transferred and the respective reportable segment for each of the 2022 acquisitions (in millions):

	PreOmics GmbH			Optimal Industrial Automation and Technologies			Inscopix, Inc.
Segment	BSI CALID			BSI BioSpin			BSI Nano
Consideration Transferred:
Cash paid	$	52.1		$	40.3		$	101.5
Cash acquired		(16.0	)		(6.2	)		(12.1	)
Fair value of hybrid financial instruments - founders		20.9			—			—
Fair value of redeemable noncontrolling interest - other shareholders		6.8			—			—
Fair value of contingent consideration		—			0.4			—
Working capital adjustment		—			—			0.6
Total consideration transferred	$	63.8		$	34.5		$	90.0
Allocation of Consideration Transferred:
Accounts receivable	$	0.4		$	1.9		$	3.2
Inventories		0.6			—			2.5
Other current assets		0.7			0.8			0.9
Property, plant and equipment		1.3			0.1			0.5
Other assets		0.4			0.8			4.7
Intangible assets:
Technology		12.5			5.9			26.6
Customer relationships		6.9			12.9			20.8
Backlog		—			1.1			—
Trade name		1.9			1.2			3.2
Goodwill		47.0			18.6			52.2
Liabilities assumed		(7.9	)		(8.8	)		(24.6	)
Total consideration allocated	$	63.8		$	34.5		$	90.0

Schedule of Consideration Transferred and the Respective Reporting Segment for Each Acquisition

Name of Acquisition	Date Acquired	Segment	Total Consideration		Cash Consideration
Prolab Instruments GmbH	January 17, 2022	BSI CALID	$	5.7	$	5.5
PepSep Holding ApS	February 1, 2022	BSI CALID		4.1		2.8
IonSense, Inc	April 5, 2022	BSI CALID		9.5		8.1
Neurescence, Inc.	November 30, 2022	BSI Nano		7.5		7.1
			$	26.8	$	23.5

In addition to the acquisitions noted above, in 2022 the Company completed minority strategic investments that complemented the Company’s existing product offerings. The following table (in millions) reflects the consideration transferred and the respective reportable segment for the investments. For those investments accounted for under the alternative measurement these values also represent the carrying value at December 31, 2022. No impairments have been recognized on these investments.

Name	Acquisition / Investment	Financial Statement Classification	Date Acquired	Segment	Total Consideration		Cash Consideration
PrognomiQ, Inc	Investment	Other long-term assets	February 16, 2022	BSI CALID	$	12.0	$	12.0
Tofwerk, AG	Investment	Other long-term assets	April 28, 2022	BSI CALID		18.6		18.6
Kiyatec, Inc	Investment	Other long-term assets	November 23, 2022	BSI CALID		9.3		9.3
Other Investments	Investment	Other long-term assets	Various	BSI CALID		20.3		20.3
					$	60.2	$	60.2